Related Experiment Video
Updated: Jun 23, 2025
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Contemporary Insights Into HIV Esophagitis: Pathogenesis, Therapeutic Strategies, and Prognostic Outcomes
Dhruvikumari D Sharma1, Peter Girgis2, Dhruv Gandhi3
1Medicine, Avalon University School of Medicine, Willemstad, CUW.
Abstract:
Opportunistic infections caused by various bacteria, viruses, fungi, or parasites can cause esophagitis. The fungus Candida albicans is often believed to be the thief behind this disorder. This condition's distinctive signs include the process of inflammation and the development of esophageal ulcers. The underlying immunodeficiency condition in HIV/AIDS patients, especially those in the late stages of the disease, may lead to severe illness or even death if the lowered immune system can no longer combat common infections. These individuals are, therefore, more at risk of contracting diseases like Candidiasis since they already have weakened immune systems. Furthermore, bacteria and mycobacteria can cause esophagitis in the same way that viruses can. Tobacco use, alcohol drinking, and nutritional deficiency are three additional problems that can lead to an HIV esophagitis infection. Complaints of inability to swallow, suffocating feeling or discomfort behind the breastbone, and painful swallowing are the primary symptoms of the patients. White plaques or ulcers observed in the esophagus during an endoscopy can be biopsied for further examination. The presence of C. albicans hyphae and inflammatory infiltrates in these samples confirms the diagnosis of HIV-associated esophagitis. Treatment involves the use of antifungal medications and addressing any underlying causes of esophagitis, which is linked to AIDS. For superficial to moderate infections, fluconazole is typically used first. If the disease is severe or recurs after treatment, intravenous amphotericin B may be necessary. Patients with recurring oral symptoms of HIV esophagitis might also need to take antifungal drugs as a preventative measure.
Insights
HIV-associated esophagitis, often caused by Candida albicans, leads to inflammation and ulcers in the esophagus. Treatment involves antifungals and addressing underlying immunodeficiency in HIV/AIDS patients.
Area of Science:
- Infectious Diseases
- Gastroenterology
- Immunology
Background:
- Opportunistic infections, including fungal, bacterial, and viral pathogens, can cause esophagitis.
- Individuals with Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS), particularly in advanced stages, are highly susceptible to esophagitis due to weakened immune systems.
- Risk factors for HIV-associated esophagitis include tobacco use, alcohol consumption, and nutritional deficiencies.
Purpose of the Study:
- To summarize the causes, symptoms, diagnosis, and treatment of esophagitis in the context of HIV/AIDS.
- To highlight the role of Candida albicans as a common pathogen in HIV-associated esophagitis.
- To discuss management strategies for both superficial and severe cases of HIV-associated esophagitis.
Main Methods:
- Review of clinical presentations and diagnostic findings associated with esophagitis in HIV/AIDS patients.
- Endoscopic examination with biopsy for histopathological confirmation of pathogens like Candida albicans and inflammatory markers.
- Analysis of treatment protocols, including antifungal medications and management of underlying conditions.
Main Results:
- Esophagitis in HIV/AIDS patients is characterized by inflammation and esophageal ulcers, frequently linked to Candida albicans.
- Symptoms include dysphagia, odynophagia, and retrosternal discomfort.
- Histological examination of biopsies confirms the presence of pathogens and inflammatory infiltrates, establishing the diagnosis.
Conclusions:
- HIV-associated esophagitis is a significant opportunistic infection in immunocompromised individuals, primarily caused by Candida albicans.
- Prompt diagnosis through endoscopy and biopsy, followed by appropriate antifungal therapy (e.g., fluconazole, amphotericin B), is crucial for effective management.
- Addressing underlying immunodeficiency and risk factors is essential for preventing recurrence and improving patient outcomes.
Related Concept Videos
01:21Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
01:26Esophageal Strictures-II: Clinical Features and Management
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
01:23Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
01:10Retrovirus Life Cycles